Tamil Nadu

About Authors:
^*1P.SanilKumar, ¹C K. Dhanapal, ²Sandhya Ravi
¹Department of Pharmacy,
Annamali University, AnnamaliNager,
Chidambaram, Tamilnadu.
²Lotus Labs Pvt Ltd,
No.07, Jasmabhavan Road, Vasanthanager, Bangalore, Karnataka.
*sanilmpharm@gmail.com

ABSTRACT
Hospitals are created for cure the disease but not for the spreading of diseases, even though this statement is true to the theoretical concept but it is not possible practically due to various risk factors. The spread of infection in the hospitals occurs due to the microorganism. Nosocomial infections add significantly to the economic burden of managing the underlying disease that has lead to hospitalization of the patient. More than 90% of reported infections are bacterial where as viral, fungal or protozoal infections are less commonly involved in hospital-acquired infections. This project deals with bacterial nosocomial pathogens only, since they are by far major causes of nosocomial infections. Objective of the present study include  the identification, prevention and control of nosocomial infection in our hospitals. The ultimate aim is the reduction of nosocomial infections and their costs. Baseline study for morbidity pattern in the hospitals, finding sources of exogenous and endogenous sources of nosocomial infection. Suggest measures to minimize the nosocomial infections and suggest guidelines for efficacious management of nosocomial infections.

Micro therapeutic Research Labs (MTR) is a quality driven, full service oriented Clinical Research Organization (CRO) that provides a broad range of clinical research services to the global pharmaceutical and biotechnology industry.
Situated in three different locations namely Selaiyur, Coimbatore and Padi in Tamilnadu, the southern part of India; Micro Therapeutic Research Labs offers you world-class services that are truly customized for your unique research requirements.

Shasun Pharmaceutical Division develops and manufactures formulations for solid dosage products. Shasun Pharmaceutical Division develops and manufactures formulations for solid dosage products. The Division is a vertically integrated formulations partner for the pharmaceutical industry.

Laila group is inviting applications from dedicated scientist to become a part of new innovative and exploratory research program for developing molecules/Nutraceuticals /Botanical drugs for unmet medical needs.

EPIDermizz, a skincare division of Nippon Seiyaku Pvt. Ltd. Nippon Seiyaku Pvt. Ltd. is an associate of Nippon Seiyaku co. Ltd., Japan which have been started its operation in Indian Market in 2001. Having robust brand NUTRIFACTS, Nippon is one of the most admired companies in pediatric fraternity. It has the history of pioneering in the area of nutrition by launching molecules like Methylcobalamine, Benfothiamine and Co Enzyme Q10 first time in India.

Wockhardt today, is distinguished by a strong and growing presence in the world's leading markets, with more than 65% of its revenue oming from Europe and the United States. Wockhardt's market presence covers formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).

About Authors:
S.Kameshwaran^1*, V.Suresh¹, M.Mohanraj^2
1Department of pharmacology,
JKK munirajah medical research foundation and College of Pharmacy,
B.Komarapalayam, Namakkal, Tamilnadu - 638183
²Marineboitoxinology labs, CAS in marine biology, Annamalai university,
Chidambaram, Tamilnadu-608502
*kamesh.pharm@gmail.com

ABSTRACT
Tecoma stans flowers have been traditionally used for many ailments including cancer. In the present study, anti cancer activity of methanolic flower extract of T.stans (METS) was evaluated using both in vitro and in vivo methods. METS was subjected to preliminary qualitative phytochemical investigations by using standard procedures. In vitro antitumor activity of METS was evaluated by the MTT assay methodusing Vero and HEP-2 cell lines. Then the extract subjected to in vivo anti cancer activity using Ehrlich ascites carcinoma (EAC) tumor model. The activity was assessed Increase in life span, average increase in body weight, changes in food intake, tumor volume, tumor weight, viable cell count, non viable cell count, PCV, Total cell count and hematological studies. The potency of the extract was compared with standard 5-flurouracil (20 mg/kg i.p.).In in vitro anti cancer activity METS exhibited significant cytotoxic activity against both cell lines even at different concentrations. Oral administration of METS at the dose of 200 and 400 mg/Kg, significantly (p < 0.001) increased the survival time, non viable cell count and decreased the average body weight and food intake, viable cell count of the tumor bearing mice. After 14 days of inoculation, METS was able to reverse the changes in the hematological parameters, protein and PCV consequent to tumor inoculation.The results indicate that METS possess significant antitumor activity on dose dependent manner.